Journal of Gastroenterology

, Volume 48, Issue 11, pp 1234–1241 | Cite as

Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin

  • Katsunobu Oyama
  • Sachio Fushida
  • Masahide Kaji
  • Toshiya Takeda
  • Shinichi Kinami
  • Yasuo Hirono
  • Katsuhiro Yoshimoto
  • Kazuhisa Yabushita
  • Hisashi Hirosawa
  • Yuki Takai
  • Tatsuo Nakano
  • Hironobu Kimura
  • Toshiaki Yasui
  • Atsushi Tsuneda
  • Tomoya Tsukada
  • Jun Kinoshita
  • Takashi Fujimura
  • Tetsuo Ohta
Original Article—Alimentary Tract



We aimed to evaluate the efficacy of a new combination antiemetic therapy comprising aprepitant, granisetron, and dexamethasone in gastric cancer patients undergoing chemotherapy with cisplatin and S-1.


Gastric cancer patients scheduled to receive their first course of chemotherapy with cisplatin (60 mg/m2) and S-1 (80 mg/m2) were treated with a new combination antiemetic therapy aprepitant, granisetron, and dexamethasone on day 1; aprepitant and dexamethasone on days 2 and 3; and dexamethasone on day 4. The patients reported vomiting, nausea, use of rescue therapy, and change in the amount of diet intake, and completed the Functional Living Index-Emesis (FLIE) questionnaire. The primary endpoint was complete response (CR; no emesis and use of no rescue antiemetics) during the overall study phase (0–120 h after cisplatin administration). The secondary endpoints included complete protection (CP; CR plus no significant nausea); change in the amount of diet intake; and the impact of chemotherapy-induced nausea and vomiting (CINV) on daily life during the overall, acute (0–24 h), and delayed (24–120 h) phases.


Fifty-three patients were included. CR was achieved in 88.7, 98.1, and 88.7 % of patients in the overall, acute, and delayed phases, respectively. The corresponding rates of CP were 67.9, 96.2, and 67.9 %. Approximately half of the patients had some degree of anorexia. FLIE results indicated that 79.5 % of patients reported “minimal or no impact of CINV on daily life”.


Addition of aprepitant to standard antiemetic therapy was effective in gastric cancer patients undergoing treatment with cisplatin and S-1.


Aprepitant Gastric cancer CINV Anorexia QOL 


Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Bender CM, McDaniel RW, Murphy-Ende K, Pickett M, Rittenberg CN, Rogers MP, et al. Chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs. 2002;6:94–102.CrossRefPubMedGoogle Scholar
  2. 2.
    de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, v Beurden V, Stoter G, et al. Patient perceptions of the side effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer. 1997;76:1055–61.Google Scholar
  3. 3.
    Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer. 2003;97:2880–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Lindley CM, Hirsch JD, O’Neill CV, Transau MC, Gilbert CS, Osterhaus JT. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res. 1992;1:331–40.CrossRefPubMedGoogle Scholar
  5. 5.
    Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24:4472–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K, Peschel C, Eichler HG, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol. 2004;15:526–36.CrossRefPubMedGoogle Scholar
  7. 7.
    Tavorath R, Hesketh PJ. Drug treatment of chemotherapy-induced delayed emesis. Drugs. 1996;52:639–48.CrossRefPubMedGoogle Scholar
  8. 8.
    Ettinger DS, Bierman PJ, Bradbury B, Comish CC, Ellis G, Ignoffo RJ, et al. Antiemesis. J Natl Compr Canc Netw. 2007;5:12–33.PubMedGoogle Scholar
  9. 9.
    du Bois A, Meerpohl HG, Vach W, Kommoss FG, Fenzl E, Pfleiderer A. Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. Eur J Cancer. 1992;28:450–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist. 1999;4:191–6.PubMedGoogle Scholar
  11. 11.
    Kris MG, Cubeddu LX, Gralla RJ, Cupissol D, Tyson LB, Venkatraman E, et al. Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. Cancer. 1996;78:2193–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Aapro MS, Alberts DS. High-dose dexamethasone for prevention of cisplatin-induced vomiting. Cancer Chemother Pharmacol. 1981;7:11–4.CrossRefPubMedGoogle Scholar
  13. 13.
    Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol. 1999;17:2971–94.PubMedGoogle Scholar
  14. 14.
    Jantunen IT, Kataja VV, Muhonen TT. An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer. 1997;33:66–74.CrossRefPubMedGoogle Scholar
  15. 15.
    Latreille J, Pater J, Johnston D, Laberge F, Stewart D, Rusthoven J, et al. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16:1174–8.PubMedGoogle Scholar
  16. 16.
    Tsukada H, Hirose T, Yokoyama A, Kurita Y. Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis. Eur J Cancer. 2001;37:2398–404.CrossRefPubMedGoogle Scholar
  17. 17.
    Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer. 2003;39:1074–80.CrossRefPubMedGoogle Scholar
  18. 18.
    Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21:4112–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, et al. Aprepitant Protocol 054 Study Group. Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090–8.Google Scholar
  20. 20.
    Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol. 2006;17:1000–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21(Supplement 5):v232–43.CrossRefPubMedGoogle Scholar
  22. 22.
    Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29: 4189–98.Google Scholar
  23. 23.
    JSCO Guidelines for Antiemetics in Oncology 2010. 1st ed. Tokyo: Kanehara shuppan; 2010.Google Scholar
  24. 24.
    Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.CrossRefPubMedGoogle Scholar
  25. 25.
    Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C. Assessing the impact of chemotherapy-induced nausea and vomiting on patients’ daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer. 2003;11:522–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Satou A, Yamazaki T, Nukariya N, Nakamachi M, Shimada K, Matsukawa M, et al. Development of a Japanese version of the FLIE. Gan To Kagaku Ryoho. 2002;29:281–91.PubMedGoogle Scholar
  27. 27.
    Stephenson J, Davies A. An assessment of aetiology-based guidelines for the management of nausea and vomiting in patients with advanced cancer. Support Care Cancer. 2006;14:348–53.CrossRefPubMedGoogle Scholar
  28. 28.
    Tonini G, Vincenzi B, Santini D. New drugs for chemotherapy-induced nausea and vomiting: focus on palonosetron. Expert Opin Drug Metab Toxicol. 2005;1:143–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14:1570–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone and aprepitant. J Support Oncol. 2006;4:403–8.PubMedGoogle Scholar
  31. 31.
    Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer. 2008;112:2080–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Grunberg SM, Dugan M, Muss H, Wood M, Burdette-Radoux S, Weisberg T, Siebel M, et al. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer. 2009;17:589–94.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan 2013

Authors and Affiliations

  • Katsunobu Oyama
    • 1
  • Sachio Fushida
    • 1
  • Masahide Kaji
    • 2
  • Toshiya Takeda
    • 3
  • Shinichi Kinami
    • 4
  • Yasuo Hirono
    • 5
  • Katsuhiro Yoshimoto
    • 6
  • Kazuhisa Yabushita
    • 7
  • Hisashi Hirosawa
    • 8
  • Yuki Takai
    • 9
  • Tatsuo Nakano
    • 10
  • Hironobu Kimura
    • 11
  • Toshiaki Yasui
    • 12
  • Atsushi Tsuneda
    • 13
  • Tomoya Tsukada
    • 1
  • Jun Kinoshita
    • 1
  • Takashi Fujimura
    • 1
  • Tetsuo Ohta
    • 1
  1. 1.Department of Gastroenterological SurgeryKanazawa UniversityKanazawaJapan
  2. 2.Department of SurgeryToyama Prefectural Central HospitalToyamaJapan
  3. 3.Department of SurgeryPublic Central Hospital of Matto IshikawaHakusanJapan
  4. 4.Department of General and Digestive SurgeryKanazawa Medical UniversityKahokuJapan
  5. 5.First Department of SurgeryUniversity of FukuiFukuiJapan
  6. 6.Department of SurgeryToyama Rosai HospitalUozuJapan
  7. 7.Department of SurgeryTakaoka City HospitalTakaokaJapan
  8. 8.Department of SurgeryToyama City HospitalToyamaJapan
  9. 9.Department of GastroenterologyKeiju Medical CenterNanaoJapan
  10. 10.Department of SurgeryAsanogawa General HospitalKanazawaJapan
  11. 11.Department of SurgeryNTT West Kanazawa HospitalKanazawaJapan
  12. 12.Department of SurgeryKanazawa Social Insurance HospitalKanazawaJapan
  13. 13.Department of SurgeryKurobe City HospitalKurobeJapan

Personalised recommendations